Starting from the 2.8-Å resolution x-ray structure of bovine rhodopsin, three-dimensional molecular models of the complexes between arginine vasopressin and two receptor subtypes (V 1a, V 1b ) have been built. Amino acid sequence alignment and docking studies suggest that four key residues 
Starting from the 2.8-Å resolution x-ray structure of bovine rhodopsin, three-dimensional molecular models of the complexes between arginine vasopressin and two receptor subtypes (V 1a, V 1b ) have been built. Amino acid sequence alignment and docking studies suggest that four key residues (1. A RGININE VASOPRESSIN (AVP) IS a neurohypophysial nonapeptide hormone that exerts major physiological roles upon binding to three receptor subtypes regulating blood pressure (V 1a subtype), ACTH release, stress and anxiety (V 1b subtype also named V 3 ), and water reabsorption in the kidney (V 2 subtype) (1, 2) . Both receptor subtypes have been cloned in various species and belong to the wide family of G proteincoupled receptors (GPCRs) characterized by a typical heptahelical transmembrane (TM) domain (3) . AVP receptors are prototypes of peptidergic GPCRs (4) able to accommodate significantly different binding modes peptide or nonpeptide ligands (agonists and/or antagonists) and thus are particularly interesting for determining fine molecular features responsible for ligand binding (5) . The combination of molecular modeling, covalent labeling, and site-directed mutagenesis (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) has shed light on hypothetical binding modes of AVP or close analogs [oxytocin (OT), vasotocin] to their specific receptors, although a clear consensus on the exact binding mode is still missing for two main reasons. First, most recognition models further investigated by site-directed mutagenesis studies have been proposed from either an ancient x-ray structure of bacteriorhodopsin (6, 9) , which is not a GPCR, or a low-resolution map of bovine rhodopsin (7, 8, (10) (11) (12) 14) . Second, three-dimensional models based on the more recent high-resolution x-ray structure of bovine rhodopsin are still lacking experimental validation (15, 16) . Although previous models may probably not be used for accurate structure-based design, they have proven their utility to partially map the binding site of AVP. AVP is a nonapeptide (CYFQNCPRG-NH 2 ) exhibiting a 20-membered tocin ring resulting from a disulfide bridge between both cysteine residues. The conclusion of most studies is that the hydrophobic part of the molecule is accommodated by an hydrophobic pocket (Met 3.36 , Trp 6.48 , Phe 6.51 ) lying deep in the 7-TM cavity between TMs III, V, VI, and VII, whereas conserved glutamine residues (Gln 2.61 , Gln 3.32 , Gln 4.60 , Gln 6.55 ) located at the rim of the cavity H bonds to the polar part of the peptide hormone (main chain atoms as well as Gln4 and Asn5 side chains) (8, 9) . Last, the C-terminal amidated tripeptide probably projects toward a region between TMI and the second extracellular loop (8, 9) . Therefore, there is a consensus about the critical receptor residues important for AVP recognition and binding but not on the precise molecular interactions developed by each of the Starting from recent three-dimensional (3-D) models of both V 1a and V 1b receptors that are able to accurately predict the binding mode of nonpeptide antagonists (17) (18) (19) , we herewith present a high-resolution model of AVP in complex with each of its two receptor subtypes. Proposed 3-D models, compatible with most known experimental data, have been successfully challenged by site-directed mutagenesis focusing on yet undisclosed peptide-receptor interactions. Binding and functional properties of six mutants of the V 1a or the V 1b human receptor were investigated using either AVP or the recently described d [Cha 4 ]AVP analog exhibiting a nice V 1b selectivity profile for human vasopressin receptor subtypes (20) .
RESULTS

3-D Molecular Modeling
Aligning the amino acid sequences of vasopressin/OT receptors with that of bovine rhodopsin is rather straightforward because rhodopsin-like fingerprints (21, 22) are common to all entries (Fig. 1) . The modeled structure of V 1a and V 1b receptor subtypes, although simulated in an explicitly hydrated phospholipid membrane, remains quite close to the x-ray structure of bovine rhodopsin [root mean square deviation (rmsd) on backbone TM residues between 1.2 and 1.3 Å]. AVP adopts a rather similar binding mode to both V 1a and V 1b receptor models ( Fig. 2 and Table 1 ), which recalls earlier binding modes described by Mouillac et al. (8) and Thibonnier et al. (9) . With respect to the starting conformation taken from the structure of neurophysin-bound OT (23), a ␤-turn is still observed in AVP but shifted from positions 2-5 to positions 3-6. Interestingly, the receptor-bound conformation of AVP to V 1a and V 1b receptor subtypes is similar to that recently proposed for density functional theory (DFT)-optimized Zn 2ϩ -bound OT (24) (rmsd of 0.8 Å on backbone atoms of the tocin ring). Carbonyl moieties at positions 2, 3, 6, and 8 converge toward a common region that could accommodate a dicationic ion, as proposed for OT (24) . Transmembrane helices (TMI-TMVII) are delimited by gray boxes. Amino acids residues mutated in this work are enclosed by white boxes. Down arrows indicate residues pointing inwards the TM binding cavity (37) . Position 50 in Ballesteros numbering (27) of each TM is marked by a vertical bar.
A full description of intermolecular interactions between AVP and both receptor subtypes is listed in Table 1 . A very tiny network of hydrogen bonds (16) (17) (18) (19) (20) H bonds) is used to anchor AVP to its receptor subtypes. Most residues proposed to participate in AVP binding have been shown to be of crucial importance for agonist peptide binding (8) (9) (10) (11) . Key features of the proposed models involve hydrophobic interactions of Tyr2 side chain with a first apolar pocket between TMVI and TMVII, and of Phe3 aromatic ring with an apolar pocket delineated between TMIII and TMVI. Important hydrogen bonds are established between Gln4 side chain and Q 4.60 , Asn5 side chain, and Q 6.55 for anchoring the tocin ring to the transmembrane cavity (Table 1) . By opposition to previously described models (8, 9) , a well-defined negatively charged subsite (E 1.35 , D 2.65 ) perfectly accommodates the positively charged Arg8 side chain (Fig. 3, A Our 3-D models were then used to find a plausible explanation to the previously described nice selectivity profile of d [Cha 4 ]AVP, a desamino-cys-1 analog of AVP bearing a cyclohexylalanine side chain at position 4 (20) . In contrast to AVP, which does not distinguish V 1a from V 1b subtype with regard to binding affinity, d [Cha 4 ]AVP exhibits a much stronger affinity for the human V 1b receptor than for the human V 1a subtype (Table 3) . A previous report demonstrated that a hydrophobic side chain at position 4 is clearly responsible for the favored binding to the human V 1b subtype (20) . Modeling the complex between the latter AVP analog and V 1a /V 1b receptor subtypes did not reveal major changes in the binding mode with respect to the previously described recognition model of endogenous AVP. A close-up view of amino acids contacting the Cha4 side chain provides a reasonable explanation for the selectivity profile of d 4 ]AVP with a much higher affinity of the peptide analog for the double mutant than for the wild-type V 1a receptor ( Table 3 ). The Y 4.61 V mutation also weakly, but significantly, increased the affinity of the selective V 1b antagonist SSR149415 to the V 1a mutant. Strikingly, the S 5.35 P change affected SSR149415 binding only when presented together with the Y 4.61 V mutation. Last, the binding properties of the selective V 1a agonist F 180 or antagonist SR49059 were almost unchanged by any of the two mutations either alone or in combination (Table 3) .
Mutating residues 4.61 and 5.35 affected more the functional properties of the human V 1a receptor as compared with binding parameters. Both single mutants were much more efficient than the wild-type V 1a receptor in stimulating phospholipase C by AVP or d [Cha 4 ]AVP. Yet these effects were of weak amplitude (Table 4 , Fig. 6 ). In contrast to our previous observation concerning d [Cha 4 ]AVP binding properties, the double mutant did not confer any significant functional gain with respect to the single mutants.
DISCUSSION
A precise mapping of molecular interactions between peptide ligands and their receptors is a prerequisite for designing nonpeptide agonists for therapeutic applications. Taking advantage of the high-resolution structure of bovine rhodopsin (3), the only G proteincoupled receptor crystallized to date, we have developed homology models for two AVP receptor subtypes (V 1a , V 1b ) in an explicit hydrated phospholipid environment and docked AVP and a recently described analog (d[Cha 4 ]AVP) to each receptor model. AVP is proposed to interact quite similarly with V 1a and V 1b receptor subtypes (Fig. 2 , A and B) in agreement with previously described site-directed mutagenesisguided mapping of the AVP binding site in the latter receptors (8, 9, 14) . To experimentally challenge the yet undisclosed molecular partners of arginine 8 residue of AVP, the two negatively charged residues (E (Table 2) . Because both residues are fully conserved in all V 1a and V 1b receptor subtypes (Fig. 1) , it is likely that the herein predicted interaction is a common feature of AVP recognition by the latter subtypes. The present model and its experimental validation also exclude the possibility that the neighboring Y 2.68 amino acid in V 1a and V 1b receptors directly interacts with Arg8, as previously reported in earlier recognition models (10), because the Y 2.68 A mutation has no influence on AVP binding to the V 1b mutated receptor ( is also used by other peptide agonists, especially E 1. 35 , which seems to be a common anchor to all ligands tested herein whatever their selectivity for individual subtypes (Tables 3 and 5) . Lysine vasopressin for which the arginine 8 has been replaced by a lysine is also sensitive to both mutations, which can be easily explained by lysine's potential to develop ionic interactions with the two negatively charged residues. To further evidence the direct interaction between arginine 8 and E Quite surprisingly, both mutations also decrease the binding affinity of a nonpeptidic V 1b antagonist The two TM helices (I and II) as well as the first extracellular loop (e1) at the vicinity of Arg8-contacting residues are displayed by gray ribbons and tube, respectively. The Arg8 main chain and side chain atoms of AVP are displayed by a dark tube and ball-and-sticks, respectively. V 1a amino acids are labeled according to the SwissProt numbering with the Ballesteros numbering indicated in superscript. (SSR149415, Table 3 ) the previously mapped binding site of which (18) (Fig. 7) . The effect of both above reported mutations on the binding of SSR149415 is difficult to rationalize from the present interaction model because direct molecular interactions between ligand and mutated residues are unlikely. During this work, the same E 1.35 A mutation has been described for the V 1a receptor subtype and reported to dramatically decrease AVP binding and signaling but also to have no influence on the affinity of the selective V 1a nonpeptidic antagonist SR49059 (25) . The binding site of SR49059 to the human V 1a receptor has already been mapped by our laboratory (19) and demonstrated to largely overlap that of the V 1b antagonist SSR149415 (18) . At present, we have no clear explanation for the differential consequences of E 1.35 A mutation on V 1a and V 1b nonpeptidic antagonists. Among possible explanations, this precise mutation may result in subtle conformational changes remotely affecting the antagonist binding site in the V 1b subtype.
To furthermore challenge the herein described 3-D models, we took advantage of the fine selectivity profile of a recently described V 1b peptide agonist (d [Cha 4 ]AVP), an analog of dAVP ([deaminocys1]arginine vasopressin) (20) for which glutamine 4 has been changed to cyclohexylalanine (Cha) and which exhibits a 70-fold higher affinity for the V 1a subtype than for the V 1b subtype (Table 3) . Our 3-D Fig. 1 ) and 3-D models (Fig. 8) clearly shows that the above-described pocket is significantly more polar in V 1a (Y 4.61 , S/T 5.35 ) than in V 1b receptors (V 4.61 , P 5.35 ). Therefore, it is logical that AVP analogs exhibiting hydrophobic residues are the most selective for the V 1b receptor subtype (20) . To further validate this hypothesis, the two variable residues in the human V 1a receptor were mutated to their V 1b counterparts (Y186V, S213P). The two single and the double mutation had no effect on AVP binding (Table 3) because AVP does not discriminate between both subtypes, probably because of a tight hydrogen bond between Gln4 side chain and the conserved Q 4.60 (Table 1) . The K i of the selective V 1b agonist d [Cha 4 ]AVP was also not really modified by single mutations, but a drastic gain in affinity was observed for the double mutant (Table 3) , thus confirming our starting hypothesis. It is likely that single mutations in this plastic hydrophobic subsite are compensated by slight conformational rearrangements that do not occur upon double mutation. Interestingly, the coupling properties of the mutant receptors to phospholipase C were already affected by single mutations (Table 4 ) and much closer to that of wild-type V 1b than wild-type V 1a receptor. Contrary to our previous observations, the double mutation does not here confer a better V 1b pharmacological profile to the V 1a double mutant ( Table 4 ).
The present sequence alignment (Fig. 1 ) also provides a good explanation for the d [Cha 4 ]AVP pharmacological species differences previously observed for vasopressin V 2 receptors (26) . Hence, the only difference in the above-reported Cha4 binding pocket between human and rat V 2 subtypes lies precisely at position 5.35 ( Fig. 1) . In the human V 2 subtype, position 5.35 is a bulky and positively charged amino acid (Arg), which is probably not suited to accommodate a bulky hydrophobic side chain at position 4 of the peptide ligand. Mutation to a smaller and more hydrophobic residue (Leu) in the rat V 2 receptor is therefore beneficial to the binding of d [Cha 4 ]AVP (Table 5) . Conversely, AVP analogs with smaller polar side chains (e.g. lysine vasopressin) do not distinguish human from rat V 2 receptors (Table 5 ). It is difficult from the present data to explain the selective binding of d [Cha 4 ]AVP to the human V 1B receptor vs. human OT receptor (26) . Strikingly, AVP itself does not distinguish between those receptors. These subtle differences are probably beyond the accuracy of the current homology models. It is still possible that the human OT receptor has slightly different orientation and kinks of the seven helices when bound to d [Cha 4 ]AVP. The proposed interaction models, however, should be valuable to design novel selective agonists, notably by focusing on some positions (5.42 and 7.39 for example) which vary across the AVP receptor family and which also explain the selective binding of nonpeptide V 1b antagonists (18) .
In conclusion, receptor modeling of human AVP receptors in complex with AVP and d[Cha 4 ]AVP, a se- lective V 1b agonist, shed light on putative molecular interactions between the peptide hormone and its receptors. Validation of the computational models by studying the binding and coupling properties of a few mutants on V 1a and V 1b receptor unambiguously demonstrate that arginine-8, a very important residue for ligand binding, interacts with a set of negatively charged amino acids (E 1.35 , D 2.65 ) at V 1a and V 1b receptor subtypes. Moreover, a rational explanation to the V 1b -selective binding of d [Cha 4 ]AVP is proposed and confirmed by site-directed mutagenesis. Altogether, the refined 3-D models of V 1a and V 1b human receptors in complex with peptide agonists should facilitate the identification of selective and nonpeptidic V 1a and V 1b agonists as pharmacological but also therapeutic tools.
MATERIALS AND METHODS
Residue Numbering and Nomenclature
The residue numbering proposed by Ballesteros et al. (27) was used throughout this manuscript. It allows an unambiguous comparison of TM residues for any class A GPCR by assigning position 50 to a fully conserved amino acid at each TM (Asn for TMI, Asp for TMII, Arg for TMIII, Trp for TMIV, Pro for TMs V-VII; see Fig. 1 ) and numbering other amino acids according to this reference residue. Residue x.y is thus the amino acid describing position y of TMx. For purposes of clarification, amino acids from the peptide ligands will be labeled using a three-letter code whereas receptor residues will be labeled using a single-letter code.
Alignment of Amino Acid Sequences
The amino acid sequences of human and rat AVP and OT receptor subtypes were retrieved from the Swiss-Prot database (accession nos: human V 1a receptor, P37288; rat V 1a receptor, P30560, human V 1b receptor, P47901; rat V 1b receptor, P48974; human V 2 receptor, P30518; rat V 2 receptor, Q00788; human OT receptor, P30559; rat OT receptor, P70536) and aligned to the sequence of bovine rhodopsin (accession no. P02699) using the in-house developed GPCRmod program (21) focusing on transmembrane (TM) domains only. The alignment of the amino and carboxy-terminal domains as well as of the intra-and extracellular loops was realized using ClustalW (28) . A slow pairwise alignment using BLOSUM matrix series (29) and a gap opening penalty of 15.0 were chosen for aligning the amino acid sequences to the sequence of bovine rhodopsin. Only TM helices (labeled from I-VII) are shown as red ribbons for sake of clarity. Two negatively-charged residues (E 1.35 and D 2.65 ) the mutation of which decreases the binding affinity of the two ligands (Tables 2 and 3 ) are shown by white (carbon) and red (oxygen) sticks. The ligand (blue sticks) is shown along with its molecular surface (magenta for AVP, green for SSR14915). The figure was prepared and rendered with VIDA2 (OpenEye Scientific Software, Santa Fe, NM). (17) (18) (19) . To achieve an agonist-bound model from an antagonist-bound model, we followed, for each receptor subtype, a five-step protocol as proposed by Bissantz et al. (17) . In a first step, only the first and third extracellular loops between helices 2 and 3, and helices 6 and 7, respectively, were included in a preliminary model. In a second step, AVP was docked to this preliminary model using the Gold 2.1 program (30) . For each of the 10 independent genetic algorithm (GA) runs, a maximum number of 1000 GA operations was performed on a single population of 50 individuals. Operator weights for crossover, mutation, and migration were set to 100, 100, and 0, respectively. To allow poor nonbonded contacts at the start of each GA run, the maximum distance between hydrogen donors and fitting points was set to 5 Å, and nonbonded van der Waals energies were cut off at a value equal to kij (well depth of the van der Waals energy for the atom pair i,j). To further speed up the calculation, the GA docking was stopped when the top three solutions were within 1.5 Å rmsd. If this criterion is met, we can assume that these top solutions represent a reproducible pose for the ligand. It should be observed that the starting conformation of AVP was modeled from the x-ray structure of neurophysin-bound OT (23) . In a third step, the receptor-AVP complex was minimized with AMBER8.0 (31) using the AMBER03 force field to relax the structure and to remove steric bumps. In a fourth step, the extracellular loop 2 between helices 4 and 5 and the N-terminal region were added to the model through a simple knowledge-based loop search procedure as previously described (17) . The disulfide bridge present between Cys 3.25 and a conserved Cys in the extracellular 2 loop was kept unchanged with respect to the x-ray structure of bovine rhodopsin (3) . After the heavy atoms were modeled, all hydrogen atoms were added, and the protein coordinates were then minimized again with AMBER. The minimizations were carried out by 1000 steps of steepest descent followed by conjugate gradient minimization until the rms gradient of the potential energy was lower than 0.05 kcal/mol⅐Å. A twin cutoff (10.0, 15.0 Å) was used to calculate nonbonded electrostatic interactions at every minimization step, and the nonbonded pair list was updated every 25 steps. A distance-dependent ( ϭ 4r) dielectric function was used. Last, the complex was embedded in a preequilibrated lipid bilayer consisting in 70 molecules of palmitoyloleoylphosphatidylcholine and solvated by 11,588 TIP3P water molecules (box dimensions: 86.6 * 93.1 * 78.0 Å) as recently described by Urizar et al. (32) . A short minimization was applied to the complex embedded in the hydrated lipid bilayer using AMBER8.0 and applying a positional harmonic constraint of 50 kcal/mol⅐Å on C␣ carbons. A 1-nsec constant pressure molecular dynamics (MD) simulation was then applied to the entire system. Periodic boundaries and Particle Mesh Ewald summation were considered to treat electrostatic interactions. All bonds involving hydrogen atoms were frozen with the SHAKE algorithm, thus enabling the selection of a 2-fsec integration step. During the first 250 psec, the ␣-carbons were constrained as previously described, and the temperature was linearly increased from 0 to 300 K. In the productive part of the MD simulation (last 750 psec), the temperature was fixed to 300 K by coupling to a heat bath using a coupling constant of 0.2. All atoms were free to move, energies and coordinates were saved every 10 psec. The analysis of the MD trajectories was realized using the ptraj module of AMBER8.0.
Automated Docking of d[Cha 4 ]AVP
The docking of d [Cha 4 ]AVP to the two receptor models was done as described for AVP.
Site-Directed Mutagenesis
All the mutations were generated into the human V 1a or V 1b receptor sequence. The human V 1a and V 1b cDNA inserted into the pRK5 expression vector was kindly provided by Dr. B. Mouillac. Amino acid replacements were generated by PCR using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA), as previously described (26) . For single amino acid replacements of mutants E37A, D95A, and Y98A, cDNA of the wild-type human V 1b receptor was used as the template with the appropriate mutated oligonucleotide primers. For replacements of Y186V and S213P mutants, cDNA from V 1a receptor was used as the template. The double mutant Y186V/S213P was generated as described above using cDNA of the Y186V mutant as the template and mutated oligonucleotide primers corresponding to the S213P mutation. Each construct was transformed, amplified in the Escherichia coli DH5-␣ strain (Invitrogen, Cergy-Pontoise, France), and then purified with the QIAprep Spin Miniprep Kit (QIAGEN, Courtaboeuf, France). All the mutations were verified by sequencing (Genome Express, Meylan, France).
cDNA Expression of Wild-Type and Mutant Vasopressin Receptors and Cell Culture
The human V 1a and V 1b wild-type receptors were stably expressed in CHO cells as previously described (26) . The mutants of the human V 1a or V 1b receptors were transiently expressed in CHO cells by electroporation. Briefly, the cells (10 7 /0.3 ml) were resuspended in an electroporation buffer (50 mM K 2 HPO 4 ; 20 mM C 2 H 3 KO 2 ; 20 mM KOH; pH 7.4) with 20 g of carrier DNA (pRK5 expression vector without insert) and 0.5-2.0 g of the expression vector containing the mutated receptor cDNA and 40 mM MgSO 4 . They were then incubated for 20 min at room temperature before being pulsed [280 V, 950 microfarads; Bio-Rad Apparatus (Bio-Rad Laboratories, Hercules, CA)]. CHO cells expressing the wildtype and mutated vasopressin receptors were plated in 150-mm Petri dishes or 24-well plates depending upon the experiment to be conducted. Cells were cultured 48 h at 37 C in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 500 U/ml penicillin and streptomycin, and nonessential amino acids (1ϫ) in an atmosphere of 95% air and 5% CO 2 . Sodium butyrate (3 mM) was added in the incubation medium for the last 24 h.
Membrane Preparation
CHO cells, stably or transiently transfected with wild-type or mutated receptors, were washed twice in PBS without CaCl 2 and MgCl 2 , harvested in lysis buffer (15 mM Tris-HCl, pH 7.4; 2 mM MgCl 2 ; 0.3 mM EDTA), polytron homogenized, and centrifuged at 44,000 ϫ g for 20 min at 4 C. Pellets were washed in a Buffer A (50 mM Tris-HCl, pH 7.4; 3 mM MgCl 2 ) and centrifuged at 44,000 ϫ g for 20 min at 4 C. Membranes were resuspended in a small volume of Buffer A. Protein concentration was determined by the method of Bradford with the Bio-Rad protein assay kit and using BSA as a standard. Membranes were stored at Ϫ80 C before use.
Binding Experiments
Membrane binding assays were performed as previously described using [ 3 H]AVP as radioligand. Membranes (5-10 g protein) were incubated 60 min. at 30 C in a medium containing: 50 mM Tris-HCl, pH 7.4; 3 mM MgCl 2 ; 1 mg⅐ml Ϫ1 BSA; and 0.01 mg⅐ml Ϫ1 leupeptin. Affinity (K d ) of [ 3 H]AVP for the wild-type and the mutated vasopressin receptors was determined by saturation experiments using concentrations of labeled vasopressin ranging from 0.1 to 30 nM. For each concentration of radioligand, total and nonspecific binding was determined in absence or presence, respectively, of 1 M unlabeled AVP. The affinities (K i ) of the unlabeled analogs were determined by competition experiments. Briefly, depending upon the receptors studied, 0.5 to 15 nM of [ 3 H]AVP was added in the incubation medium with or without increasing amounts of the unlabeled analogs to be tested (total binding). Nonspecific binding was determined under the same experimental conditions in the presence of 1 M unlabeled AVP. The radioactivity found associated with plasma membranes was determined by filtration through glass microfiber filters (GF/C Series; Whatman International Ltd., Maidstone, UK). Specific binding was calculated and expressed as percent of the maximal binding capacity determined without unlabeled analog. K i values were calculated from the dose-displacement curves fitted with the Cheng and Prusoff equation.
IP Assays
Total IP accumulation was determined as previously described. Briefly, CHO cells stably or transiently transfected with the wild-type and the mutated receptors were grown for 24 h in DMEM supplemented with 10% fetal calf serum. Cells were further incubated for another 24-h period in a serum and inositol-free medium supplemented with 1Ci⅐ml Ϫ1 myo-[ 3 H]-inositol and 3 mM sodium butyrate. Cells were then washed twice with a Hanks' buffered saline (HBS) medium, equilibrated at 37 C in HBS for 30 min, and incubated for 15 min in HBS supplemented with 15 mM LiCl, 1 mg⅐ml Ϫ1 glucose, 1 mg⅐ml Ϫ1 BSA and 2.1 g⅐liter Ϫ1 NaHCO 3 . Cells were further stimulated for 15 min with increasing concentrations of the analogs to be tested. Reaction was stopped by adding perchloric acid (5% vol/vol, final concentration). IPs accumulated were extracted and purified on Dowex AG1-X8 anion exchange chromatography column as previously described (26) and counted.
Chemicals
All reagents used were of analytical grade. Most standard chemicals were purchased from Sigma (St. Louis, MO), Roche Molecular Biochemicals (Mannheim, Germany), or Merck & Co., Inc. (Darmstadt, Germany), unless otherwise indicated. AVP came from Bachem (Bubendorf, Switzerland). 
Data Analysis
The radioligand binding data were analyzed by GraphPad Prism (GraphPad Software, Inc., San Diego, CA). The dissociation constants (K d ) of the radioligands were determined according to the Scatchard linearization of the saturation curve obtained (33) . The inhibitory dissociation constants (K i ) for unlabeled analogs were calculated from binding competition experiments according to the Cheng and Prusoff equation ( 
